Wu Jianming, Ke Xiao, Fu Wei, Gao Xiaoping, Zhang Hongcheng, Wang Wei, Ma Na, Zhao Manxi, Hao Xiaofeng, Zhang Zhirong
Laboratory of Chinese Materia Medica, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, Sichuan, China.
Post-Doctoral Research Station, KangHong Pharmaceutical Group, Chengdu 610036, Sichuan, China.
Molecules. 2016 Dec 21;21(12):1756. doi: 10.3390/molecules21121756.
Specnuezhenide (SPN), one of the main ingredients of Chinese medicine "Nü-zhen-zi", has anti-angiogenic and vision improvement effects. However, studies of its effect on retinal neovascularization are limited so far. In the present study, we established a vascular endothelial growth factor A (VEGFA) secretion model of human acute retinal pigment epithelial-19 (ARPE-19) cells by exposure of 150 μM CoCl₂ to the cells and determined the VEGFA concentrations, the mRNA expressions of VEGFA, hypoxia inducible factor-1α (HIF-1α) & prolyl hydroxylases 2 (PHD-2), and the protein expressions of HIF-1α and PHD-2 after treatment of 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole (YC-1, 1.0 μg/mL) or SPN (0.2, 1.0 and 5.0 μg/mL). Furthermore, rat pups with retinopathy were treated with SPN (5.0 and 10.0 mg/kg) in an 80% oxygen atmosphere and the retinal avascular areas were assessed through visualization using infusion of ADPase and H&E stains. The results showed that SPN inhibited VEGFA secretion by ARPE-19 cells under hypoxia condition, down-regulated the mRNA expressions of VEGFA and PHD-2 slightly, and the protein expressions of VEGFA, HIF-1α and PHD-2 significantly in vitro. SPN also prevented hypoxia-induced retinal neovascularization in a rat model of oxygen-induced retinopathy in vivo. These results indicate that SPN ameliorates retinal neovascularization through inhibition of HIF-1α/VEGF signaling pathway. Therefore, SPN has the potential to be developed as an agent for the prevention and treatment of diabetic retinopathy.
女贞子苷(SPN)是中药“女贞子”的主要成分之一,具有抗血管生成和改善视力的作用。然而,目前关于其对视网膜新生血管作用的研究有限。在本研究中,我们通过用150μM氯化钴处理人急性视网膜色素上皮-19(ARPE-19)细胞建立了血管内皮生长因子A(VEGFA)分泌模型,并在加入3-(5'-羟甲基-2'-呋喃基)-1-苄基吲唑(YC-1,1.0μg/mL)或SPN(0.2、1.0和5.0μg/mL)处理后,测定了VEGFA浓度、VEGFA、缺氧诱导因子-1α(HIF-1α)和脯氨酰羟化酶2(PHD-2)的mRNA表达,以及HIF-1α和PHD-2的蛋白表达。此外,在80%氧气环境中,用SPN(5.0和10.0mg/kg)处理患有视网膜病变的幼鼠,并通过ADP酶灌注和苏木精-伊红染色可视化评估视网膜无血管区。结果表明,在体外缺氧条件下,SPN抑制ARPE-19细胞分泌VEGFA,轻微下调VEGFA和PHD-2的mRNA表达,显著下调VEGFA、HIF-1α和PHD-2的蛋白表达。在体内氧诱导视网膜病变大鼠模型中,SPN还可预防缺氧诱导的视网膜新生血管形成。这些结果表明,SPN通过抑制HIF-1α/VEGF信号通路改善视网膜新生血管形成。因此,SPN有潜力被开发成为预防和治疗糖尿病视网膜病变的药物。